170 related articles for article (PubMed ID: 34983046)
21. Nonmelanoma Skin Cancer Risk in Patients With Inflammatory Bowel Disease Undergoing Thiopurine Therapy: A Systematic Review of the Literature.
Hagen JW; Pugliano-Mauro MA
Dermatol Surg; 2018 Apr; 44(4):469-480. PubMed ID: 29315147
[TBL] [Abstract][Full Text] [Related]
22. Outcome of concomitant treatment with thiopurines and allopurinol in patients with inflammatory bowel disease: A nationwide Danish cohort study.
Thomsen SB; Allin KH; Burisch J; Jensen CB; Hansen S; Gluud LL; Theede K; Kiszka-Kanowitz M; Nielsen AM; Jess T
United European Gastroenterol J; 2020 Feb; 8(1):68-76. PubMed ID: 32213059
[TBL] [Abstract][Full Text] [Related]
23. NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.
Kakuta Y; Kawai Y; Okamoto D; Takagawa T; Ikeya K; Sakuraba H; Nishida A; Nakagawa S; Miura M; Toyonaga T; Onodera K; Shinozaki M; Ishiguro Y; Mizuno S; Takahara M; Yanai S; Hokari R; Nakagawa T; Araki H; Motoya S; Naito T; Moroi R; Shiga H; Endo K; Kobayashi T; Naganuma M; Hiraoka S; Matsumoto T; Nakamura S; Nakase H; Hisamatsu T; Sasaki M; Hanai H; Andoh A; Nagasaki M; Kinouchi Y; Shimosegawa T; Masamune A; Suzuki Y;
J Gastroenterol; 2018 Sep; 53(9):1065-1078. PubMed ID: 29923122
[TBL] [Abstract][Full Text] [Related]
24. Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease.
Vasudevan A; Beswick L; Friedman AB; Moltzen A; Haridy J; Raghunath A; Sparrow M; van Langenberg D
Dig Liver Dis; 2018 Jul; 50(7):682-688. PubMed ID: 29525182
[TBL] [Abstract][Full Text] [Related]
25. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.
Dulai PS; Thompson KD; Blunt HB; Dubinsky MC; Siegel CA
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1443-51; quiz e88-9. PubMed ID: 24462626
[TBL] [Abstract][Full Text] [Related]
26. Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA Registry.
Calafat M; Mañosa M; Mesonero F; Guardiola J; Mínguez M; Nos P; Vera I; Taxonera C; Iglesias E; Ricart E; Gisbert JP; Calvet X; García-López S; Monfort D; Pérez Calle JL; Riestra S; Gomollón F; Garcia-Planella E; Bermejo F; Hernández V; Martín-Arranz MD; Gutiérrez A; Torres P; Cañete F; Domènech E;
J Crohns Colitis; 2020 Sep; 14(9):1290-1298. PubMed ID: 32201893
[TBL] [Abstract][Full Text] [Related]
27. Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease.
Lopez A; Mounier M; Bouvier AM; Carrat F; Maynadié M; Beaugerie L; Peyrin-Biroulet L;
Clin Gastroenterol Hepatol; 2014 Aug; 12(8):1324-9. PubMed ID: 24582568
[TBL] [Abstract][Full Text] [Related]
28. Increased risk of thiopurine-related adverse events in elderly patients with IBD.
Calafat M; Mañosa M; Cañete F; Ricart E; Iglesias E; Calvo M; Rodríguez-Moranta F; Taxonera C; Nos P; Mesonero F; Martín-Arranz MD; Mínguez M; Gisbert JP; García-López S; de Francisco R; Gomollón F; Calvet X; Garcia-Planella E; Rivero M; Martínez-Cadilla J; Argüelles F; Arias L; Cimavilla M; Zabana Y; Domènech E;
Aliment Pharmacol Ther; 2019 Oct; 50(7):780-788. PubMed ID: 31429097
[TBL] [Abstract][Full Text] [Related]
29. The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: results from a population-based cohort in Eastern Europe.
Lakatos PL; Lovasz BD; David G; Pandur T; Erdelyi Z; Mester G; Balogh M; Szipocs I; Molnar C; Komaromi E; Golovics PA; Vegh Z; Mandel M; Horvath A; Szathmari M; Kiss LS; Lakatos L
J Crohns Colitis; 2013 Jun; 7(5):385-91. PubMed ID: 22766526
[TBL] [Abstract][Full Text] [Related]
30. Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy.
Musumba CO
Aliment Pharmacol Ther; 2013 Nov; 38(9):1025-37. PubMed ID: 24099468
[TBL] [Abstract][Full Text] [Related]
31. The risk of non-melanoma skin cancer in New Zealand in inflammatory bowel disease patients treated with thiopurines.
Bahi M; Walmsley RS; Gray AR; Young D; Hobbs CE; Aluzaite K; Schultz M
J Gastroenterol Hepatol; 2018 May; 33(5):1047-1052. PubMed ID: 29105142
[TBL] [Abstract][Full Text] [Related]
32. Optimizing thiopurine therapy in inflammatory bowel disease.
Chevaux JB; Peyrin-Biroulet L; Sparrow MP
Inflamm Bowel Dis; 2011 Jun; 17(6):1428-35. PubMed ID: 20949566
[TBL] [Abstract][Full Text] [Related]
33. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts.
Jharap B; Seinen ML; de Boer NK; van Ginkel JR; Linskens RK; Kneppelhout JC; Mulder CJ; van Bodegraven AA
Inflamm Bowel Dis; 2010 Sep; 16(9):1541-9. PubMed ID: 20155846
[TBL] [Abstract][Full Text] [Related]
34. Leukopenia predicts remission in patients with inflammatory bowel disease and Behcet's disease on thiopurine maintenance.
Park MS; Kim DH; Kim DH; Park SJ; Hong SP; Kim TI; Kim WH; Cheon JH
Dig Dis Sci; 2015 Jan; 60(1):195-204. PubMed ID: 25239495
[TBL] [Abstract][Full Text] [Related]
35. Systematic review with meta-analysis: risk factors for thiopurine-induced leukopenia in IBD.
van Gennep S; Konté K; Meijer B; Heymans MW; D'Haens GR; Löwenberg M; de Boer NKH
Aliment Pharmacol Ther; 2019 Sep; 50(5):484-506. PubMed ID: 31342537
[TBL] [Abstract][Full Text] [Related]
36. Thiopurine therapy in inflammatory bowel disease.
Ha C; Dassopoulos T
Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):575-88. PubMed ID: 20932143
[TBL] [Abstract][Full Text] [Related]
37. EBV Status and Thiopurine Use in Pediatric IBD.
Gordon J; Ramaswami A; Beuttler M; Jossen J; Pittman N; Lai J; Dunkin D; Benkov K; Dubinsky M
J Pediatr Gastroenterol Nutr; 2016 May; 62(5):711-4. PubMed ID: 26655944
[TBL] [Abstract][Full Text] [Related]
38. Have we overestimated the risk of lymphoma associated with thiopurine treatment for ulcerative colitis?
Kumar AR; Dudnick RS
Gastroenterology; 2014 Apr; 146(4):1131. PubMed ID: 24576738
[No Abstract] [Full Text] [Related]
39. Mutagenicity and potential carcinogenicity of thiopurine treatment in patients with inflammatory bowel disease.
Nguyen T; Vacek PM; O'Neill P; Colletti RB; Finette BA
Cancer Res; 2009 Sep; 69(17):7004-12. PubMed ID: 19706768
[TBL] [Abstract][Full Text] [Related]
40. Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review.
Subramaniam K; D'Rozario J; Pavli P
J Gastroenterol Hepatol; 2013 Jan; 28(1):24-30. PubMed ID: 23094824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
